Eli Lilly has selected a site near Richmond, Virginia, for its first fully integrated active pharmaceutical ingredient (API) and drug product facility dedicated to bioconjugates including antibody-drug conjugates (ADCs). This $5 billion investment is part of Lilly’s broader plan to significantly expand U.S. manufacturing capacity for cancer, autoimmune, and other therapies. The new plant underscores Lilly’s commitment to U.S. innovation, job creation, and supply chain resilience amid increasing domestic demand for complex biologics manufacturing. The announcement aligns with industry-wide growth trends and federal incentives aiming to bolster pharmaceutical production on U.S. soil.